COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

NCT05518487 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

COVID-19
Kidney Transplant

Interventions

BIOLOGICAL: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]